Skip to main content
. 2016 Jul 27;90(16):7497–7507. doi: 10.1128/JVI.00297-16

TABLE 1.

Clinical characteristics of HSCT recipients included in this study

Code Recipient/donor serostatus HLA type No. of episodes of CMV reactivation Maximal CMV titer Days posttransplant that the CMV load was >600 copies/ml CMV disease
Patients with CMV reactivationa
    04 R+/D A2 A29 B44 B51 Cw1 4 10,000 60–70, 144–158, 189–195, 363–391 Yes: CMV colitis
    06 R+/D A23 A26 B39 B51 Cw2 1 900 64–71 No
    13 R+/D A2 A29 B44 B62 Cw3 Cw16 2 12,000 33–67, 77–84 No
    14 R+/D+ A11 A31 B7 B60 6 120,000 46–55, 139–178, 192–196, 213–217, 249–269, 286–314 Yes: CMV enteritis
    16 R+/D A2 A24 B15 B27 Cw2 Cw3 1 870 69 No
    17 R+/D A1 A24 B08 B39 Cw7 2 40,000 37, 44–68 No
    19 R+/D+ A2 A24 B44 Cw5 3 55,000 32–64, 73–80, 88–92 No
    25 R+/D A2 A3 B35 B62 Cw3 Cw10 2 2,400 59, 95–102 No
    26 R+/D A2 A33 B14 B15 Cw3 Cw8 3 4,100 35–60, 81–88, 273–277 No
    28 R+/D A2 A24 B44 Cw5 Cw6 1 6,800 46–67 No
    30 R+/D+ A2 A24 B13 B60 Cw3 Cw4 1 64,000 314–332 No
    32 R+/D A2 B13 B40 Cw3 Cw6 5 22,000 39, 49–63, 151–157, 179, 192–237 No
    34 R+/D A1 A33 B8 B14 Cw7 Cw8 1 2,000 57–64 No
    38 R+/D+ A1 A24 B41 B57 Cw6 Cw17 1 1,400 75–92 No
    39 R+/D A2 A29 B44 Cw5 1 6,900 45–62 No
    44 R+/D+ A2 A32 B18 B44 Cw5 Cw7 1 1,000 43–48 No
    46 R+/D A2 B27 B44 Cw2 Cw5 2 2,800 32–35, 53 No
Patients without CMV reactivation
    01 R+/D A1 A3 B27 B60 Cw2 Cw3 NAb NA NA No
    07 R/D+ A1 A2 B08 B15 Cw3 Cw7 NA NA NA No
    15 R+/D A3 A31 B7 B60 Cw3 Cw7 NA NA NA No
    36 R+/D A1 A2 B35 B62 Cw3 Cw4 NA NA NA No
    37 R+/D A2 A23 B15 B44 Cw4 Cw7 NA NA NA No
    42 R+/D+ A2 A23 B15 B44 Cw4 Cw7 NA NA NA No
    43 R+/D+ A1 A26 B44 B13 Cw7 NA NA NA No
    45 R+/D A1 A2 B37 B44 Cw5 Cw6 NA NA NA No
    47 R+/D+ A2 B7 B44 Cw5 Cw7 NA NA NA No
a

CMV reactivation is defined as CMV DNAemia of >600 copies/ml.

b

NA, not applicable.